# Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

> **NCT03578432** · EARLY_PHASE1 · TERMINATED · sponsor: **University of Arizona** · enrollment: 2 (actual)

## Conditions studied

- Salivary Gland Dysfunction
- Xerostomia
- Head and Neck Cancer

## Interventions

- **DRUG:** Everolimus
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Survey Administration

## Key facts

- **NCT ID:** NCT03578432
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-04
- **Primary completion:** 2019-11-15
- **Final completion:** 2019-11-15
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** UACC-PHX is no longer able to support the study and Novartis is unable to provide drug beyond December 2019.
- **Last updated:** 2019-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03578432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03578432, "Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03578432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*